Výsledky vyhľadávania - "Myelodysplastic Syndromes drug therapy"

Lenalidomide in Transfusion-Dependent IPSS Low- or Intermediate-1-Risk Myelodysplastic Syndromes and Isolated Del(5q): Results of a European Postauthorization Safety Surveillance Study: Results of a European Postauthorization Safety Surveillance Study

Autori: Antonella Poloni Klas Raaschou-Jensen Francisca Hernandez Mohedo a ďalší

Zdroj: Clinical Lymphoma Myeloma and Leukemia. 25:e131-e142

Predmety: Blood Transfusion/statistics & numerical data, Male, Adult, overall survival, Chromosomes, Deletion 5q, 80 and over, Humans, Blood Transfusion, immunomodulatory imide drug, Lenalidomide, Aged, Aged, 80 and over, Acute myeloid leukemia, noninterventional study, Myelodysplastic Syndromes/drug therapy, Middle Aged, Prognosis, Europe, Lenalidomide/therapeutic use, Myelodysplastic Syndromes, Chromosomes, Human, Pair 5, Female, Pair 5, Chromosome Deletion, Human

Prístupová URL adresa: https://pubmed.ncbi.nlm.nih.gov/39516085
https://portal.findresearcher.sdu.dk/da/publications/ade4f66f-7f0e-46bd-bfe0-c02f9feb891a
https://doi.org/10.1016/j.clml.2024.10.007

Treatment with the apoptosis inhibitor Asunercept reduces clone sizes in patients with lower risk Myelodysplastic Neoplasms

Autori: Streuer, Alexander Jann, Johann-Christoph Boch, Tobias a ďalší

Zdroj: Ann Hematol

Predmety: 0301 basic medicine, 03 medical and health sciences, 0302 clinical medicine, Bone Marrow, Research, Neoplasms, Myelodysplastic Syndromes, Mutation, Mutation [MeSH], Neoplasms [MeSH], Myelodysplastic Neoplasms, Clone Cells/pathology [MeSH], Humans [MeSH], Myelodysplastic Syndromes/genetics [MeSH], Apoptosis [MeSH], Asunercept, Myelodysplastic Syndromes/drug therapy [MeSH], Bone Marrow/pathology [MeSH], APG101, Targeted therapies, Myelodysplastic Syndromes/pathology [MeSH], Apoptosis inhibitor, Humans, Apoptosis, Clone Cells

Prístupová URL adresa: https://pubmed.ncbi.nlm.nih.gov/38413410
https://repository.publisso.de/resource/frl:6491718

Fludarabine-treosulfan versus fludarabine-melphalan or busulfan-cyclophosphamide conditioning in older AML or MDS patients – A clinical trial to registry data comparison

Autori: Dietrich Wilhelm Beelen Simona Iacobelli Linda Koster a ďalší

Prispievatelia: Dietrich Wilhelm Beelen Simona Iacobelli Linda Koster a ďalší

Zdroj: Bone Marrow Transplant

Predmety: Male, Transplantation Conditioning, Medizin, Settore MEDS-09/B - Malattie del sangue, Article, Antineoplastic Combined Chemotherapy Protocols, Busulfan/pharmacology [MeSH], 692/308/2779/109, Transplantation Conditioning/methods [MeSH], Aged [MeSH], Myelodysplastic Syndromes/therapy [MeSH], Leukemia, Myeloid, Acute/mortality [MeSH], Cyclophosphamide/therapeutic use [MeSH], Melphalan/administration, Melphalan/therapeutic use [MeSH], Cyclophosphamide/administration, Vidarabine/analogs, Busulfan/analogs, Vidarabine/pharmacology [MeSH], Male [MeSH], Busulfan/therapeutic use [MeSH], Myelodysplastic Syndromes/drug therapy [MeSH], 692/700/565/2319, Leukemia, Myeloid, Acute/therapy [MeSH], Myelodysplastic Syndromes/mortality [MeSH], Female [MeSH], Vidarabine/administration, Humans [MeSH], Vidarabine/therapeutic use [MeSH], Middle Aged [MeSH], Melphalan/pharmacology [MeSH], Antineoplastic Combined Chemotherapy Protocols/therapeutic use [MeSH], Busulfan/administration, Cyclophosphamide/pharmacology [MeSH], Antineoplastic Combined Chemotherapy Protocols/pharmacology [MeSH], Hematopoietic Stem Cell Transplantation/methods [MeSH], Leukemia, Myeloid, Acute/drug therapy [MeSH], Registries [MeSH], article, Humans, Registries, Busulfan, Cyclophosphamide, Melphalan, Aged, Hematopoietic Stem Cell Transplantation, Middle Aged, Settore MED/15, 3. Good health, [SDV] Life Sciences [q-bio], Settore MED/01, Leukemia, Myeloid, Acute, antineoplastic combined chemotherapy protocols, busulfan, cyclophosphamide, Myelodysplastic Syndromes, Female, Vidarabine

Popis súboru: application/pdf

Prístupová URL adresa: https://pubmed.ncbi.nlm.nih.gov/38383713
https://repository.publisso.de/resource/frl:6521917

Imetelstat in patients with lower-risk myelodysplastic syndromes who have relapsed or are refractory to erythropoiesis-stimulating agents (IMerge): a multinational, randomised, double-blind, placebo-controlled, phase 3 trial

Autori: Platzbecker, Uwe Santini, Valeria Fenaux, Pierre a ďalší

Zdroj: The Lancet. 403:249-260

Predmety: Male, Adult, Adolescent, Oligonucleotides, Thrombocytopenia, 3. Good health, Treatment Outcome, Double-Blind Method, Myelodysplastic Syndromes, Antineoplastic Combined Chemotherapy Protocols, Humans, Female, Erythropoiesis, Myelodysplastic Syndromes / drug therapy telomerase inhibitor imetelstat anemia Treatment Outcome

Popis súboru: application/pdf

Prístupová URL adresa: https://pubmed.ncbi.nlm.nih.gov/38048786
https://hdl.handle.net/2158/1357997
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)01724-5/abstract
https://doi.org/10.1016/s0140-6736(23)01724-5

VEXAS Syndrome: Complete molecular remission after hypomethylating therapy

Autori: Sockel, Katja Götze, Katharina Ganster, Christina a ďalší

Prispievatelia: Sockel, Katja Götze, Katharina Ganster, Christina a ďalší

Zdroj: Ann Hematol

Predmety: Azacitidine [MeSH], Azacitidine, Hypomethylating therapy, Humans [MeSH], Myelodysplastic Syndromes/drug therapy [MeSH], Pathologic Complete Response [MeSH], Prospective Studies [MeSH], Molecular remission, Antimetabolites, Antineoplastic [MeSH], Skin Diseases, Genetic [MeSH], VEXAS, Case Report, 0301 basic medicine, Antimetabolites, Antineoplastic, 0303 health sciences, Skin Diseases, Genetic, ddc, 3. Good health, 03 medical and health sciences, Myelodysplastic Syndromes, Pathologic Complete Response, Humans, Prospective Studies

Popis súboru: application/pdf

Prístupová URL adresa: https://pubmed.ncbi.nlm.nih.gov/38214707
https://resolver.sub.uni-goettingen.de/purl?gro-2/140251
https://repository.publisso.de/resource/frl:6500667
https://mediatum.ub.tum.de/1770942

Higher MDMX expression was associated with hypomethylating agent resistance and inferior survival in MDS patients, inferring it a potential therapeutic target

Autori: Yu-Hung Wang Chien-Chin Lin Kristian Gurashi a ďalší

Zdroj: Wang, Y-H, Lin, C-C, Gurashi, K, Wingelhofer, B, Amaral, F M R, Yao, C-Y, Hsieh, H T, Liu, M C, Hou, H-A, Chou, W-C, Batta, K, Wiseman, D H & Tien, H-F 2023, 'Higher MDMX expression was associated with hypomethylating agent resistance and inferior survival in MDS patients, inferring it a potential therapeutic target', Leukemia, vol. 37, no. 12, pp. 2507-2511. https://doi.org/10.1038/s41375-023-02044-2

Predmety: Myelodysplastic Syndromes, Azacitidine, Humans, Myelodysplastic Syndromes/drug therapy, Prognosis, Azacitidine/pharmacology

Prístupová URL adresa: https://pubmed.ncbi.nlm.nih.gov/37919605
https://research.manchester.ac.uk/en/publications/5e9dab90-8698-4524-a174-8151d354d8fb
https://doi.org/10.1038/s41375-023-02044-2
https://research.manchester.ac.uk/en/publications/5e9dab90-8698-4524-a174-8151d354d8fb
https://doi.org/10.1038/s41375-023-02044-2
http://www.scopus.com/inward/record.url?scp=85175624808&partnerID=8YFLogxK

Long-term utilization and benefit of luspatercept in transfusion-dependent, erythropoiesis-stimulating agent-refractory or -intolerant patients with lower-risk myelodysplastic syndromes with ring sideroblasts

Autori: Uwe Platzbecker Valeria Santini Rami S. Komrokji a ďalší

Zdroj: Leukemia

Predmety: Activin Receptors, Type II / pharmacology Erythropoiesis Hematinics / pharmacology Hematinics / therapeutic use Humans Myelodysplastic Syndromes / drug therapy, Letter, Myelodysplastic Syndromes, Activin Receptors, Type II, Hematinics, Humans, Erythropoiesis

Popis súboru: application/pdf

Prístupová URL adresa: https://pubmed.ncbi.nlm.nih.gov/37752285

'Randomized phase II study of azacitidine ± lenalidomide in higher-risk myelodysplastic syndromes and acute myeloid leukemia with a karyotype including Del(5q)'

Autori: Bengt Rasmussen Gudrun Göhring Elsa Bernard a ďalší

Prispievatelia: Bengt Rasmussen Gudrun Göhring Elsa Bernard a ďalší

Zdroj: Leukemia
Rasmussen, B, Göhring, G, Bernard, E, Nilsson, L, Tobiasson, M, Jädersten, M, Garelius, H, Dybedal, I, Grønbaek, K, Ejerblad, E, Lorenz, F, Flogegård, M, Marcher, C W, Öster Fernström, A, Cavelier, L, Papaemmanuil, E, Ebeling, F, Kittang, A O, Nørgaard, J M, Saft, L, Möllgård, L & Hellström-Lindberg, E 2022, '“Randomized phase II study of azacitidine ± lenalidomide in higher-risk myelodysplastic syndromes and acute myeloid leukemia with a karyotype including Del(5q)”', Leukemia, vol. 36, no. 5, pp. 1436-1439. https://doi.org/10.1038/s41375-022-01537-w
Rasmussen, B, Gohring, G, Bernard, E, Nilsson, L, Tobiasson, M, Jadersten, M, Garelius, H, Dybedal, I, Gronbaek, K, Ejerblad, E, Lorenz, F, Flogegard, M, Marcher, C W, oster Fernstrom, A, Cavelier, L, Papaemmanuil, E, Ebeling, F, Kittang, A O, Norgaard, J M, Saft, L, Mollgard, L & Hellstrom-Lindberg, E 2022, ' "Randomized phase II study of azacitidine ± lenalidomide in higher-risk myelodysplastic syndromes and acute myeloid leukemia with a karyotype including Del(5q)" ', Leukemia, vol. 36, no. 5, pp. 1436-1439 . https://doi.org/10.1038/s41375-022-01537-w
Rasmussen, B, Göhring, G, Bernard, E, Nilsson, L, Tobiasson, M, Jädersten, M, Garelius, H, Dybedal, I, Grønbaek, K, Ejerblad, E, Lorenz, F, Flogegård, M, Marcher, C W, Öster Fernström, A, Cavelier, L, Papaemmanuil, E, Ebeling, F, Kittang, A O, Nørgaard, J M, Saft, L, Möllgård, L & Hellström-Lindberg, E 2022, ' “Randomized phase II study of azacitidine ± lenalidomide in higher-risk myelodysplastic syndromes and acute myeloid leukemia with a karyotype including Del(5q)” ', Leukemia, vol. 36, no. 5, pp. 1436-1439 . https://doi.org/10.1038/s41375-022-01537-w

Predmety: 0301 basic medicine, Cancer och onkologi, 0303 health sciences, Letter, Karyotype, Leukemia, Myeloid, Acute/drug therapy, Chromosomes, Human, Pair 5/genetics, Hematology, Myelodysplastic Syndromes/drug therapy, 03 medical and health sciences, Lenalidomide/therapeutic use, Cancer and Oncology, Azacitidine, Humans, Hematologi, Chromosome Deletion, Cancers

Popis súboru: application/pdf

Prístupová URL adresa: http://hdl.handle.net/10138/343553
https://pure.au.dk/portal/en/publications/efeca66c-b0f8-4cd9-a714-5f06272110a9
https://curis.ku.dk/ws/files/314443731/s41375_022_01537_w.pdf
https://portal.findresearcher.sdu.dk/da/publications/4f350502-7453-432c-82cf-bdea5d480d81
https://doi.org/10.1038/s41375-022-01537-w
https://findresearcher.sdu.dk:8443/ws/files/200456566/s41375_022_01537_w.pdf
http://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-193219
http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-485158
http://www.scopus.com/inward/record.url?scp=85126099436&partnerID=8YFLogxK
https://pure.au.dk/portal/en/publications/efeca66c-b0f8-4cd9-a714-5f06272110a9
https://doi.org/10.1038/s41375-022-01537-w
https://pure.au.dk/ws/files/331573673/s41375_022_01537_w.pdf
https://publications.scilifelab.se/publication/aeb6d7967c5e4824bf38be84594fe806

Combination of treosulfan, fludarabine and cytarabine as conditioning in patients with acute myeloid leukemia, myelodysplastic syndrome and myeloproliferative neoplasms

Autori: Samantha O'Hagan Henderson Jochen J Frietsch Inken Hilgendorf a ďalší

Zdroj: J Cancer Res Clin Oncol

Predmety: Myeloproliferative Disorders, Transplantation Conditioning, Original Article – Clinical Oncology, Cytarabine, Hematopoietic Stem Cell Transplantation, Graft vs Host Disease, Middle Aged, 3. Good health, Toxicity-reduced conditioning, MDS, Transplantation Conditioning/methods [MeSH], Humans [MeSH], Vidarabine/adverse effects [MeSH], Retrospective Studies [MeSH], Middle Aged [MeSH], Myeloproliferative Disorders/drug therapy [MeSH], Allogeneic stem cell transplantation, Recurrence [MeSH], Vidarabine/analogs, Busulfan/analogs, Graft vs Host Disease [MeSH], Cytarabine/adverse effects [MeSH], Myelodysplastic Syndromes/drug therapy [MeSH], Busulfan/adverse effects [MeSH], Hematopoietic Stem Cell Transplantation/methods [MeSH], Leukemia, Myeloid, Acute/drug therapy [MeSH], MPN, AML, Leukemia, Myeloid, Acute, 03 medical and health sciences, 0302 clinical medicine, Recurrence, Myelodysplastic Syndromes, Humans, Busulfan, Vidarabine, Retrospective Studies

Prístupová URL adresa: https://link.springer.com/content/pdf/10.1007/s00432-021-03836-8.pdf
https://www.researchsquare.com/article/rs-731909/v1.pdf?c=1631901382000
https://pubmed.ncbi.nlm.nih.gov/34674031
https://pubmed.ncbi.nlm.nih.gov/34674031/
https://www.researchsquare.com/article/rs-731909/v1.pdf?c=1631901382000
https://link.springer.com/article/10.1007/s00432-021-03836-8
https://www.researchsquare.com/article/rs-731909/v1
https://repository.publisso.de/resource/frl:6446886

Preclinical evaluation of eltrombopag in a PDX model of myelodysplastic syndromes

Autori: Nanni Schmitt Johann-Christoph Jann Eva Altrock a ďalší

Zdroj: Leukemia

Predmety: Aged, 80 and over, Male, 0301 basic medicine, 0303 health sciences, Cancer models, Female [MeSH], Cell Proliferation [MeSH], Aged, 80 and over [MeSH], Myelodysplastic syndrome, Aged [MeSH], Humans [MeSH], Pyrazoles/therapeutic use [MeSH], Middle Aged [MeSH], Mice, Inbred NOD [MeSH], Animals [MeSH], Apoptosis [MeSH], Mice, SCID [MeSH], Tumor Cells, Cultured [MeSH], Mice [MeSH], Article, Preclinical research, Male [MeSH], Benzoates/therapeutic use [MeSH], Xenograft Model Antitumor Assays [MeSH], Myelodysplastic Syndromes/drug therapy [MeSH], Prognosis [MeSH], Hydrazines/therapeutic use [MeSH], Myelodysplastic Syndromes/pathology [MeSH], Apoptosis, Mice, SCID, Middle Aged, Prognosis, Benzoates, Xenograft Model Antitumor Assays, 3. Good health, Mice, 03 medical and health sciences, Hydrazines, Mice, Inbred NOD, Myelodysplastic Syndromes, Tumor Cells, Cultured, Animals, Humans, Pyrazoles, Female, Aged, Cell Proliferation

Prístupová URL adresa: https://www.nature.com/articles/s41375-021-01327-w.pdf
https://pubmed.ncbi.nlm.nih.gov/34172896
https://www.nature.com/articles/s41375-021-01327-w.pdf
https://www.nature.com/articles/s41375-021-01327-w
http://www-nature-com-443.webvpn.bjmu.tsg211.com/articles/s41375-021-01327-w
https://www.ncbi.nlm.nih.gov/pubmed/34172896
https://pubmed.ncbi.nlm.nih.gov/34172896/
https://europepmc.org/article/MED/34172896
https://repository.publisso.de/resource/frl:6443812

Luspatercept restores SDF-1-mediated hematopoietic support by MDS-derived mesenchymal stromal cells

Autori: Manja Wobus Anna Mies Nandini Asokan a ďalší

Zdroj: Leukemia

Predmety: Adult, 0301 basic medicine, 0303 health sciences, Activin Receptors, Type II, Recombinant Fusion Proteins, Mesenchymal Stem Cells, Smad2 Protein, Middle Aged, Hematopoietic Stem Cells, Hematopoietic Stem Cells/metabolism [MeSH], Immunoglobulin Fc Fragments/pharmacology [MeSH], Smad2 Protein/genetics [MeSH], Hematopoiesis [MeSH], Aged [MeSH], Mesenchymal Stem Cells/drug effects [MeSH], Translational research, Stem-cell research, Tumor Cells, Cultured [MeSH], Haematopoietic stem cells, Zebrafish [MeSH], Myelodysplastic Syndromes/drug therapy [MeSH], Activin Receptors, Type II/pharmacology [MeSH], Case-Control Studies [MeSH], Hematinics/pharmacology [MeSH], Chemokine CXCL12/metabolism [MeSH], Myelodysplastic Syndromes/pathology [MeSH], Recombinant Fusion Proteins/pharmacology [MeSH], Mesenchymal Stem Cells/pathology [MeSH], Adult [MeSH], Humans [MeSH], Chemokine CXCL12/genetics [MeSH], Middle Aged [MeSH], Animals [MeSH], Smad2 Protein/metabolism [MeSH], Hematopoietic Stem Cells/drug effects [MeSH], Myelodysplastic Syndromes/metabolism [MeSH], Mesenchymal Stem Cells/metabolism [MeSH], Article, Hematopoietic Stem Cells/pathology [MeSH], Chemokine CXCL12, Hematopoiesis, Immunoglobulin Fc Fragments, 3. Good health, 03 medical and health sciences, Case-Control Studies, Myelodysplastic Syndromes, Hematinics, Tumor Cells, Cultured, Animals, Humans, Zebrafish, Aged

Prístupová URL adresa: https://www.nature.com/articles/s41375-021-01275-5.pdf
https://pubmed.ncbi.nlm.nih.gov/34002031
https://www.ncbi.nlm.nih.gov/pubmed/34002031
https://europepmc.org/article/MED/34002031
https://www.nature.com/articles/s41375-021-01275-5.pdf
https://www.nature.com/articles/s41375-021-01275-5
https://pubmed.ncbi.nlm.nih.gov/34002031/
https://repository.publisso.de/resource/frl:6443820

Hypomethylating agents (HMA) for the treatment of acute myeloid leukemia and myelodysplastic syndromes: mechanisms of resistance and novel HMA-based therapies

Autori: John Charles Rotondo Julia Stomper Michael Lübbert a ďalší

Zdroj: Leukemia

Predmety: 0301 basic medicine, 0303 health sciences, Review Article, DNA Methylation, Acute myeloid leukaemia, Myelodysplastic syndrome, DNA Methylation/drug effects [MeSH], Drug Resistance, Neoplasm/drug effects [MeSH], Humans [MeSH], Myelodysplastic Syndromes/drug therapy [MeSH], Treatment Outcome [MeSH], Leukemia, Myeloid, Acute/drug therapy [MeSH], Animals [MeSH], Cancer therapeutic resistance, Antineoplastic Combined Chemotherapy Protocols/therapeutic use [MeSH], 3. Good health, Leukemia, Myeloid, Acute, 03 medical and health sciences, Treatment Outcome, Drug Resistance, Neoplasm, Myelodysplastic Syndromes, Antineoplastic Combined Chemotherapy Protocols, Animals, Humans

Popis súboru: application/pdf; pdf

Prístupová URL adresa: https://www.nature.com/articles/s41375-021-01218-0.pdf
https://pubmed.ncbi.nlm.nih.gov/33958699
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8257497
https://www.scilit.net/article/62f436a9a54b5df6f126037c4b8285d3
https://www.nature.com/articles/s41375-021-01218-0
https://www.ncbi.nlm.nih.gov/pubmed/33958699
https://www.nature.com/articles/s41375-021-01218-0.pdf
https://europepmc.org/article/MED/33958699
https://repository.publisso.de/resource/frl:6443840
https://hdl.handle.net/11392/2463164
https://www.nature.com/articles/s41375-021-01218-0
https://doi.org/10.1038/s41375-021-01218-0

Genome-wide DNA methylation analysis pre- and post-lenalidomide treatment in patients with myelodysplastic syndrome with isolated deletion (5q)

Autori: Hecht, Anna Meyer, Julia A. Jann, Johann-Christoph a ďalší

Prispievatelia: Hecht, Anna Meyer, Julia A. Jann, Johann-Christoph a ďalší

Zdroj: Ann Hematol

Predmety: Adult, Aged, 80 and over, Male, 0301 basic medicine, 0303 health sciences, Antineoplastic Agents, DNA Methylation, Middle Aged, ddc, 3. Good health, 03 medical and health sciences, Treatment Outcome, Myelodysplastic Syndromes, Myelodysplastic syndromes, Deletion 5q, Female [MeSH], Aged, 80 and over [MeSH], Chromosomes, Human, Pair 5/genetics [MeSH], Aged [MeSH], DNA Methylation/drug effects [MeSH], Adult [MeSH], Humans [MeSH], Lenalidomide, Treatment Outcome [MeSH], Antineoplastic Agents/pharmacology [MeSH], Middle Aged [MeSH], Myelodysplastic Syndromes/genetics [MeSH], Original Article, Male [MeSH], Myelodysplastic Syndromes/drug therapy [MeSH], Antineoplastic Agents/therapeutic use [MeSH], Chromosome Deletion [MeSH], DNA methylation, Lenalidomide/pharmacology [MeSH], Lenalidomide/therapeutic use [MeSH], Chromosomes, Human, Pair 5, Humans, Female, Chromosome Deletion, Aged

Popis súboru: application/pdf; pdf

Prístupová URL adresa: https://link.springer.com/content/pdf/10.1007/s00277-021-04492-1.pdf
https://pubmed.ncbi.nlm.nih.gov/33903952
https://link.springer.com/content/pdf/10.1007/s00277-021-04492-1.pdf
https://link.springer.com/article/10.1007/s00277-021-04492-1
https://www.ncbi.nlm.nih.gov/pubmed/33903952
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8116243
https://pubmed.ncbi.nlm.nih.gov/33903952/
https://europepmc.org/article/MED/33903952
https://resolver.sub.uni-goettingen.de/purl?gro-2/86182
https://repository.publisso.de/resource/frl:6447833
https://mediatum.ub.tum.de/doc/1618428/document.pdf

Treatment of myeloid malignancies relapsing after allogeneic hematopoietic stem cell transplantation with venetoclax and hypomethylating agents—a retrospective multicenter analysis on behalf of the German Cooperative Transplant Study Group

Autori: Esther Schuler Eva-Maria Wagner-Drouet Salem Ajib a ďalší

Prispievatelia: Esther Schuler Eva-Maria Wagner-Drouet Salem Ajib a ďalší

Zdroj: Ann Hematol

Predmety: Medizin, Kaplan-Meier Estimate, Decitabine, Leukocyte Count, 03 medical and health sciences, 0302 clinical medicine, Recurrence, Germany, Antineoplastic Combined Chemotherapy Protocols, Humans, Allografts [MeSH], Bridged Bicyclo Compounds, Heterocyclic/administration, DNA Methylation/drug effects [MeSH], DLI, Febrile Neutropenia/chemically induced [MeSH], Myelodysplastic Syndromes/therapy [MeSH], Azacitidine/administration, Salvage Therapy/adverse effects [MeSH], Leukocyte Count [MeSH], Germany/epidemiology [MeSH], Febrile Neutropenia/blood [MeSH], Sulfonamides/adverse effects [MeSH], Original Article, Decitabine/pharmacology [MeSH], Myelodysplastic Syndromes/drug therapy [MeSH], Venetoclax, Thrombocytopenia/chemically induced [MeSH], Combined Modality Therapy [MeSH], Leukemia, Myeloid, Acute/therapy [MeSH], Relapse, Thrombocytopenia/blood [MeSH], Bridged Bicyclo Compounds, Heterocyclic/adverse effects [MeSH], Transplantation Conditioning [MeSH], Drug Evaluation [MeSH], Hypomethylating agents, Kaplan-Meier Estimate [MeSH], Humans [MeSH], Azacitidine/pharmacology [MeSH], Hematopoietic Stem Cell Transplantation [MeSH], Retrospective Studies [MeSH], Allogeneic hematopoietic stem cell transplantation, Sulfonamides/administration, Antineoplastic Combined Chemotherapy Protocols/therapeutic use [MeSH], Recurrence [MeSH], Antineoplastic Combined Chemotherapy Protocols/adverse effects [MeSH], Azacitidine, Azacitidine/adverse effects [MeSH], Decitabine/administration, Immunosuppressive Agents/therapeutic use [MeSH], Leukemia, Myeloid, Acute/drug therapy [MeSH], Tumor Lysis Syndrome/etiology [MeSH], Immunosuppressive Agents/adverse effects [MeSH], Decitabine/adverse effects [MeSH], Febrile Neutropenia, Retrospective Studies, Salvage Therapy, ddc:610, Hematopoietic Stem Cell Transplantation, DNA Methylation, Allografts, Bridged Bicyclo Compounds, Heterocyclic, Combined Modality Therapy, 3. Good health, Leukemia, Myeloid, Acute, Myelodysplastic Syndromes, Drug Evaluation, Immunosuppressive Agents

Popis súboru: application/pdf

Prístupová URL adresa: https://europepmc.org/articles/pmc8448702?pdf=render
https://pubmed.ncbi.nlm.nih.gov/33191481
https://www.ncbi.nlm.nih.gov/pubmed/33191481
https://link.springer.com/content/pdf/10.1007/s00277-020-04321-x.pdf
https://pubmed.ncbi.nlm.nih.gov/33191481/
https://europepmc.org/article/MED/34160650
https://link.springer.com/article/10.1007/s00277-020-04321-x
https://repository.publisso.de/resource/frl:6467026

Lenalidomide added to standard intensive treatment for older patients with AML and high-risk MDS

Autori: G. J. Ossenkoppele D. A. Breems G. Stuessi a ďalší

Prispievatelia: G. J. Ossenkoppele D. A. Breems G. Stuessi a ďalší

Zdroj: Ossenkoppele, G J, Breems, D A, Stuessi, G, van Norden, Y, Bargetzi, M, Biemond, B J, A von dem Borne, P, Chalandon, Y, Cloos, J, Deeren, D, Fehr, M, Gjertsen, B T, Graux, C, Huls, G, Janssen, J J J W, Jaspers, A, Jongen-Lavrencic, M, de Jongh, E, Klein, S K, Van der Klift, M, Van Marwijk Kooy, M, Maertens, J, Micheaux, L, van der Poel, M W M, Van Rhenen, A, Tick, L, Valk, P, Vekemans, M C, van der Velden, W J F M, de Weerdt, O, Pabst, T, Manz, M, Löwenberg, B & for the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON) and Swiss Group for Clinical Cancer Research (SAKK) 2020, 'Lenalidomide added to standard intensive treatment for older patients with AML and high-risk MDS', Leukemia, vol. 34, no. 7, pp. 1751-1759. https://doi.org/10.1038/s41375-020-0725-0
Leukemia, 34, 7, pp. 1751-1759
Leukemia, Vol. 34, no. 7, p. 1751-1759 (2020)

Predmety: Male, 0301 basic medicine, HIGH-DOSE LENALIDOMIDE, ACUTE MYELOID-LEUKEMIA, Sciences de la santé humaine, THERAPY, 03 medical and health sciences, Leukemia, Myeloid, Acute / pathology, SDG 3 - Good Health and Well-being, Antineoplastic Combined Chemotherapy Protocols / therapeutic use, Myelodysplastic Syndromes / pathology, Antineoplastic Combined Chemotherapy Protocols, adults, Humans, Myelodysplastic Syndromes / drug therapy, Human health sciences, Lenalidomide, Haematology - Radboud University Medical Center, Aged, Aged, 80 and over, therapy, 0303 health sciences, high-dose lenalidomide, Lenalidomide / administration & dosage, Remission Induction, Cytarabine, Hematology, ADULTS, Induction Chemotherapy, Prognosis, 3. Good health, Survival Rate, Leukemia, Myeloid, Acute, Cytarabine / administration & dosage, Myelodysplastic Syndromes, Induction Chemotherapy / mortality, Radboudumc 5: Inflammatory diseases RIHS: Radboud Institute for Health Sciences, Female, acute myeloid-leukemia, Leukemia, Myeloid, Acute / drug therapy, Hématologie, Follow-Up Studies

Popis súboru: application/pdf

Prístupová URL adresa: https://pure.rug.nl/ws/files/118434471/Lenalidomide_added_to_standard_intensive_treatment_for_older_patients_with_AML_and_high_risk_MDS.pdf
https://pubmed.ncbi.nlm.nih.gov/32020044
https://hdl.handle.net/https://repository.ubn.ru.nl/handle/2066/225470
https://pure.eur.nl/en/publications/4b1aff2c-e2cb-405e-8a8b-55c872666769
https://doi.org/10.1038/s41375-020-0725-0
https://hdl.handle.net/11370/97f14b84-038f-45e9-8e79-0af373ddcd22
https://research.rug.nl/en/publications/97f14b84-038f-45e9-8e79-0af373ddcd22
https://doi.org/10.1038/s41375-020-0725-0
https://cris.maastrichtuniversity.nl/en/publications/cc27e680-8322-4302-aa67-107a6f3ccaa0
https://doi.org/10.1038/s41375-020-0725-0
https://www.nature.com/articles/s41375-020-0725-0.pdf
https://www.nature.com/articles/s41375-020-0725-0
https://research.rug.nl/en/publications/lenalidomide-added-to-standard-intensive-treatment-for-older-pati
https://www.rug.nl/research/portal/publications/lenalidomide-added-to-standard-intensive-treatment-for-older-patients-with-aml-and-highrisk-mds(97f14b84-038f-45e9-8e79-0af373ddcd22).html
https://pubmed.ncbi.nlm.nih.gov/32020044/
http://www.ncbi.nlm.nih.gov/pubmed/32020044
https://research.vumc.nl/en/publications/80af57dd-9848-40f6-b653-53245496ea78
https://pure.amsterdamumc.nl/en/publications/b2efe9ae-5634-47d6-bbb4-481825513e98
https://doi.org/10.1038/s41375-020-0725-0
https://hdl.handle.net/2066/225470
https://repository.ubn.ru.nl//bitstream/handle/2066/225470/225470.pdf
https://hdl.handle.net/2268/256384
https://doi.org/10.1038/s41375-020-0725-0
https://archive-ouverte.unige.ch/unige:182205
https://doi.org/10.1038/s41375-020-0725-0
https://hdl.handle.net/2078.1/230919

Long-term outcome of high risk patients with myelodysplastic syndromes or secondary acute myeloid leukemia receiving intensive chemotherapy.

Autori: Schuler, E. Zadrozny, N. Blum, S. a ďalší

Predmety: Adult, Age Factors, Aged, 80 and over, Disease-Free Survival, Female, Humans, Leukemia, Myeloid, Acute/drug therapy, Acute/mortality, Male, Middle Aged, Myelodysplastic Syndromes/drug therapy, Myelodysplastic Syndromes/mortality, Retrospective Studies, Risk Factors, Survival Rate, Time Factors, Induction chemotherapy, Intensive chemotherapy, MDS, Prognosis, Secondary AML

Relation: Annals of Hematology; https://iris.unil.ch/handle/iris/162546; serval:BIB_D7A4803DB8A5; 000450356200007

Dostupnosť: https://iris.unil.ch/handle/iris/162546
https://doi.org/10.1007/s00277-018-3466-7

Pevonedistat in East Asian patients with acute myeloid leukemia or myelodysplastic syndromes: a phase 1/1b study to evaluate safety, pharmacokinetics and activity as a single agent and in combination with azacitidine

Prispievatelia: Hiroshi Handa June-Won Cheong Yasushi Onishi a ďalší

Predmety: Adult, Azacitidine / therapeutic use, Cyclopentanes* / adverse effects, Cyclopentanes* / pharmacokinetics, Drug Therapy, Combination / adverse effects, Humans, Leukemia, Myeloid, Acute* / drug therapy, Myelodysplastic Syndromes* / drug therapy, Pyrimidines* / adverse effects, Pyrimidines* / pharmacokinetics, AML, East Asian, MDS, Pevonedistat, Phase 1/1b

Relation: JOURNAL OF HEMATOLOGY & ONCOLOGY; J01439; https://ir.ymlib.yonsei.ac.kr/handle/22282913/191389; T202204505

Dostupnosť: https://ir.ymlib.yonsei.ac.kr/handle/22282913/191389
https://doi.org/10.1186/s13045-022-01264-w

Benefits of hypomethylating therapy in IPSS lower-risk myelodysplastic syndrome patients: A retrospective multicenter case series study

Autori: Min Kyoung Kim Ho Sup Lee Sang Kyun Sohn a ďalší

Prispievatelia: Min Kyoung Kim Ho Sup Lee Sang Kyun Sohn a ďalší

Zdroj: Leukemia Research. 60:135-144

Predmety: Adult, Male, Antimetabolites, Antineoplastic, Antineoplastic / therapeutic use, Antimetabolites, Decitabine, Myelodysplastic Syndromes / drug therapy, Risk Assessment, Young Adult, 03 medical and health sciences, 0302 clinical medicine, 80 and over, MDS, Humans, Azacitidine / analogs & derivatives, Myelodysplastic Syndromes / mortality, Aged, Retrospective Studies, Aged, 80 and over, IPSS, Lower-risk, Middle Aged, Azacitidine / therapeutic use, Prognosis, 3. Good health, Survival Rate, Myelodysplastic Syndromes, Azacitidine, Female, Hypomethylating therapy

Prístupová URL adresa: https://pubmed.ncbi.nlm.nih.gov/28826063
https://europepmc.org/abstract/MED/28826063
http://www.sciencedirect.com/science/article/pii/S014521261730485X
https://pubmed.ncbi.nlm.nih.gov/28826063/
https://www.ncbi.nlm.nih.gov/pubmed/28826063
https://www.sciencedirect.com/science/article/pii/S014521261730485X

Adequate iron chelation therapy for at least six months improves survival in transfusion-dependent patients with lower risk myelodysplastic syndromes

Autori: Delforge, Michel Selleslag, Dominik BEGUIN, Yves a ďalší

Zdroj: Leukemia Research. 38:557-563

Predmety: Male, Risk, Time Factors, Chelation therapy, Myelodysplastic syndromes, Iron Chelating Agents -- therapeutic use, Iron Chelating Agents, Sciences de la santé humaine, 03 medical and health sciences, 0302 clinical medicine, Iron overload, Transfusion dependency, Humans, Blood Transfusion, Human health sciences, Cardiac death, Aged, Retrospective Studies, Transfusion, Hematology, Middle Aged, Myelodysplastic Syndromes -- drug therapy -- mortality, myelodysplastic syndromes, 3. Good health, Cancérologie, Myelodysplastic Syndromes, Female, Hématologie

Popis súboru: 1 full-text file(s): application/pdf

Prístupová URL adresa: https://pubmed.ncbi.nlm.nih.gov/24661630
https://core.ac.uk/display/55709442
https://arizona.pure.elsevier.com/en/publications/adequate-iron-chelation-therapy-for-at-least-six-months-improves-
https://orbi.uliege.be/handle/2268/167540
https://www.sciencedirect.com/science/article/pii/S014521261400037X
https://biblio.ugent.be/publication/5792825
https://researchportal.vub.be/en/publications/adequate-iron-chelation-therapy-for-at-least-six-months-improves-
https://hdl.handle.net/2268/167540

Multicenter study evaluating the impact of hypomethylating agents as bridging therapy to hematopoietic stem cell transplantation in myelodysplastic syndromes

Autori: Jung-Hee Lee Chul Won Cheong Yundeok Kim a ďalší

Prispievatelia: Jung-Hee Lee Chul Won Cheong Yundeok Kim a ďalší

Zdroj: International Journal of Hematology. 99:635-643

Predmety: Homologous, Adult, Male, Antimetabolites, Antineoplastic, Adolescent, Antimetabolites, Antineoplastic/therapeutic use, Young Adult, 03 medical and health sciences, Myelodysplastic Syndromes/mortality, 0302 clinical medicine, Preoperative Care, Humans, Transplantation, Homologous, DNA (Cytosine-5-)-Methyltransferases, Hypomethylating agent, 10. No inequality, Myelodysplastic Syndromes/diagnosis, Myelodysplastic Syndromes/therapy, Aged, Retrospective Studies, Transplantation, DNA (Cytosine-5-)-Methyltransferases/antagonists & inhibitors, Azacitidine/therapeutic use, Hematopoietic Stem Cell Transplantation, Middle Aged, 3. Good health, Treatment Outcome, Myelodysplastic Syndromes/drug therapy, AlloSCT, Myelodysplastic Syndromes, Azacitidine, Female, Myelodysplastic syndrome

Popis súboru: 635~643

Prístupová URL adresa: https://pubmed.ncbi.nlm.nih.gov/24648120
https://pubmed.ncbi.nlm.nih.gov/24648120/
https://europepmc.org/article/MED/24648120
https://link.springer.com/article/10.1007/s12185-014-1549-3/fulltext.html
https://link.springer.com/content/pdf/10.1007%2Fs12185-014-1549-3.pdf
https://ir.ymlib.yonsei.ac.kr/handle/22282913/138641